MedTrace Logo

Screening for Chronic Liver Diseases in General Population

NCT06366425 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2025-07-10

No results posted yet for this study

Summary

Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.

Conditions

  • Fibrosis, Liver

Interventions

DIAGNOSTIC_TEST

Blood sample then fibroscan

The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test. If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan.

Sponsors & Collaborators

  • On-call medical home (MMG) Clermont-Hérault

    collaborator UNKNOWN

  • Medical office Montpeyroux

    collaborator UNKNOWN

  • Medical office Clermont-Hérault

    collaborator UNKNOWN

  • Medical office Aniane

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Magdalena MESZAROS, MD · University Hospital, Montpellier

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2024-10-09
Completion
2029-01-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06366425 on ClinicalTrials.gov